Also trades as: CRDL.TO (TSX) · $vol 0M
CRDL NASDAQ
Cardiol Therapeutics Inc.
1W: +1.8%
1M: -34.5%
3M: -6.7%
YTD: +12.7%
1Y: -4.3%
3Y: +51.4%
5Y: -74.3%
$1.14
+0.02 (+1.79%)
Weekly Expected Move ±7.6%
$1
$1
$1
$1
$1
Credit Risk of going bust: lower than 89% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Cardiol Therapeutics Inc. would be worth roughly what it owes.
Total debt $76K against a stock market value of $135.1M.
Distance to default 13.13 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $38K (short-term plus half of long-term), stock volatility 61.1%; Altman Z'' -23.90. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $76K against a stock market value of $135.1M.
Distance to default 13.13 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $38K (short-term plus half of long-term), stock volatility 61.1%; Altman Z'' -23.90. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$137.6M
52W Range0.88-2.34
Volume312,239
Avg Volume1,211,659
Beta0.52
Dividend—
Analyst Ratings
Company Info
CEODavid G. Elsley
Employees18
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2019-01-15
Websitecardiolrx.com
2265 Upper Middle Road East
Oakville, ON L6H 0G5
CA
Oakville, ON L6H 0G5
CA
289 910 0850
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Latest News
Recent Insider Trades
No insider trades found